Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 10/2016

01-10-2016 | Meeting Report

The right patient for the right therapy: 13th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 11–13, 2015

Authors: Matthias Miller, Veronika Jahndel, Sarah Kutscher, Andrea Mahr, Richard Rae, Björn-Philipp Kloke

Published in: Cancer Immunology, Immunotherapy | Issue 10/2016

Login to get access

Excerpt

The 2015 Annual Meeting of the Association for Cancer Immunotherapy (CIMT) maintained the trend of the last CIMT meetings and with 840 participants attracted more scientists than ever before. Altogether, 77 speakers presented their data and the diverse areas of research in the field of cancer immunotherapy were discussed after the talks or in front of well over 250 posters. The overall topic was the targeted use of cutting-edge immunotherapeutic approaches by preselecting patients for a given therapy leading to the title “The right patient for the right therapy.” In this review, the highlights of the meeting are comprehensively summarized focusing on emerging trends in the field. …
Metadata
Title
The right patient for the right therapy: 13th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 11–13, 2015
Authors
Matthias Miller
Veronika Jahndel
Sarah Kutscher
Andrea Mahr
Richard Rae
Björn-Philipp Kloke
Publication date
01-10-2016
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 10/2016
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-016-1850-5

Other articles of this Issue 10/2016

Cancer Immunology, Immunotherapy 10/2016 Go to the issue

Original Article

The HB22.7–vcMMAE antibody–drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity

Original Article

Inhibition of mouse breast adenocarcinoma growth by ablation with intratumoral alpha-irradiation combined with inhibitors of immunosuppression and CpG

Original Article

Prognostic significance of HLA class I and II expression in patients with diffuse large B cell lymphoma treated with standard chemoimmunotherapy

Focussed Research Review

4-1BB agonism: adding the accelerator to cancer immunotherapy

Focussed Research Review

Modulation of innate immunity in the tumor microenvironment

Original Article

Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits